Trimetazidine Use in Parkinson’s Disease: Is It a Resolved Problem?

Trimetazidine (TMZ), an antianginal drug, can worsen the symptoms of movement disorders, therefore, the European Medicines Agency (EMA) recommended avoiding the use of this drug in Parkinson’s disease (PD). We investigated the impact of this recommendation on the observed trend of TMZ use in PD in H...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:eNeuro
Autors principals: Pintér, Dávid, Bereczki, Dániel, Ajtay, András, Oberfrank, Ferenc, Janszky, József, Kovács, Norbert
Format: Artigo
Idioma:Inglês
Publicat: Society for Neuroscience 2021
Matèries:
Research Article: New Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8143021/
https://ncbi.nlm.nih.gov/pubmed/33863783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1523/ENEURO.0452-20.2021
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars